Literature DB >> 10619728

Association between FcgammaRIIa-R131 allotype and bacteremic pneumococcal pneumonia.

A M Yee1, H M Phan, R Zuniga, J E Salmon, D M Musher.   

Abstract

Human FcgammaRIIa has 2 codominantly expressed allotypes, which differ greatly in their ability to ligate immunoglobulin G2 (IgG2). Whereas FcgammaRIIa-R131 binds only weakly to IgG2, FcgammaRIIa-H131 binds to it efficiently and might be primarily responsible for the phagocytosis of IgG2-opsonized bacteria. IgG2 plays a pivotal role in defense against pneumococcal infection. This prospective study showed that 50% of patients with bacteremic pneumococcal pneumonia were homozygous for FcgammaRIIa-R131, compared with 28% with nonbacteremic pneumococcal pneumonia and 29% of uninfected controls (P<.05). The gene frequency of FcgammaRIIa-R131 was 0.67 in bacteremic patients, significantly higher than in the other groups (P<.05). All bacteremic patients who died within 1 week of hospitalization were homozygous for FcgammaRIIa-R131. Therefore, the severity of pneumococcal infection may, in part, be genetically mediated. Taken together with similar findings in cases of meningococcal disease, these results suggest that such genetic factors may be generalizable to infections caused by encapsulated bacteria.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10619728     DOI: 10.1086/313588

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  31 in total

1.  Neutrophil responses to CRP are not dependent on polymorphism of human FcgammaRIIA (R131H).

Authors:  J A Rodríguez; K B Bodman-Smith; J G Raynes
Journal:  Clin Exp Immunol       Date:  2004-11       Impact factor: 4.330

2.  The involvement of Fc gamma receptor gene polymorphisms in Kawasaki disease.

Authors:  M Biezeveld; J Geissler; M Merkus; I M Kuipers; J Ottenkamp; T Kuijpers
Journal:  Clin Exp Immunol       Date:  2007-01       Impact factor: 4.330

Review 3.  Acute rheumatic fever and rheumatic heart disease.

Authors:  Jonathan R Carapetis; Andrea Beaton; Madeleine W Cunningham; Luiza Guilherme; Ganesan Karthikeyan; Bongani M Mayosi; Craig Sable; Andrew Steer; Nigel Wilson; Rosemary Wyber; Liesl Zühlke
Journal:  Nat Rev Dis Primers       Date:  2016-01-14       Impact factor: 52.329

4.  Dynamics of the interaction of human IgG subtype immune complexes with cells expressing R and H allelic forms of a low-affinity Fc gamma receptor CD32A.

Authors:  Rangaiah Shashidharamurthy; Fang Zhang; Aaron Amano; Aparna Kamat; Ravichandran Panchanathan; Daniel Ezekwudo; Cheng Zhu; Periasamy Selvaraj
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

5.  The Fcgamma receptor IIA-R/R131 genotype is associated with severe sepsis in community-acquired pneumonia.

Authors:  Henrik Endeman; Marie Claire A Cornips; Jan C Grutters; Jules M van den Bosch; Hendrik J T Ruven; Heleen van Velzen-Blad; Ger T Rijkers; Douwe H Biesma
Journal:  Clin Vaccine Immunol       Date:  2009-06-03

6.  Association of Fcγ receptor IIIa genotype with the rate of HIV infection after gp120 vaccination.

Authors:  Donald N Forthal; Erin E Gabriel; Angela Wang; Gary Landucci; Tran B Phan
Journal:  Blood       Date:  2012-08-22       Impact factor: 22.113

7.  Invasive pneumococcal disease in Oxford, 1985-2001: a retrospective case series.

Authors:  C C Grant; A R Harnden; G Jewell; K Knox; T E Peto; D W Crook
Journal:  Arch Dis Child       Date:  2003-08       Impact factor: 3.791

8.  Functions of Antibodies.

Authors:  Donald N Forthal
Journal:  Microbiol Spectr       Date:  2014-08-15

9.  Engineered protease-resistant antibodies with selectable cell-killing functions.

Authors:  Michelle Kinder; Allison R Greenplate; Katharine D Grugan; Keri L Soring; Katharine A Heeringa; Stephen G McCarthy; Gregory Bannish; Meredith Perpetua; Frank Lynch; Robert E Jordan; William R Strohl; Randall J Brezski
Journal:  J Biol Chem       Date:  2013-08-28       Impact factor: 5.157

10.  FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.

Authors:  Shuying S Li; Peter B Gilbert; Georgia D Tomaras; Gustavo Kijak; Guido Ferrari; Rasmi Thomas; Chul-Woo Pyo; Susan Zolla-Pazner; David Montefiori; Hua-Xin Liao; Gary Nabel; Abraham Pinter; David T Evans; Raphael Gottardo; James Y Dai; Holly Janes; Daryl Morris; Youyi Fong; Paul T Edlefsen; Fusheng Li; Nicole Frahm; Michael D Alpert; Heather Prentice; Supachai Rerks-Ngarm; Punnee Pitisuttithum; Jaranit Kaewkungwal; Sorachai Nitayaphan; Merlin L Robb; Robert J O'Connell; Barton F Haynes; Nelson L Michael; Jerome H Kim; M Juliana McElrath; Daniel E Geraghty
Journal:  J Clin Invest       Date:  2014-08-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.